ESMO Expert Report on antibody drug conjugates in the management of urothelial cancer @ASCO GU 2022

Expert video report on Urothelial Carcinoma from 2021 Genitourinary Cancers SymposiumПодробнее

The future of antibody-drug conjugates in urothelial carcinomaПодробнее

Highlights from ASCO GU 2022Подробнее

The evolving role of antibody-drug conjugates in the treatment of urothelial carcinomaПодробнее

The future of antibody-drug conjugates in urothelial cancerПодробнее

Urothelial carcinoma trial data presented at ASCO GU 2022Подробнее

Advances in antibody-drug conjugates for breast cancer at ESMO 2022Подробнее

Improving Patient Outcomes in Urothelial Carcinoma With Novel Antibody–Drug ConjugatesПодробнее

What’s next for antibody drug conjugates in urothelial carcinoma?Подробнее

Antibody-drug conjugates in urothelial carcinomaПодробнее

ADCs in the management of urothelial carcinomaПодробнее

Loncastuximab Tesirine: Breaking Down the CD19 Antibody-Drug Conjugate RevolutionПодробнее

Urothelial Carcinoma: Advances in Immuno-OncologyПодробнее

Where do ADCs fit in the treatment landscape of urothelial carcinoma?Подробнее

ESMO Lung SymposiumПодробнее

Simon Crabb and Petros Grivas on the most interesting trials presented at ASCO GU 2022.Подробнее

Highlights in Urologic Oncology from ASCO 2022Подробнее